---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-111319"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T10:06:55.116974+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics enters collaboration with WDI for hearing loss program; up to $12M funding

## Summary
- Multi-year research collaboration with William Demant Invest 2 Aps to advance ReSonance (ANPI) preclinical program for hearing loss.
- WDI will fund up to $12 million in research costs over the approximate three-year term.
- Objective: complete preclinical phase to achieve readiness for potential human clinical trials.
- IP: jointly owned project results; each party retains background IP and platform technology.
- If a party abandons, the continuing party may purchase the abandoning party's IP interest in the project.

## SEC filing metadata
- accession: 0000950170-25-111319
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025111319/0000950170-25-111319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025111319/lctx-20250826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-111319
- JSON: https://secwatch.observer/filing/0000950170-25-111319.json
- Plain text: https://secwatch.observer/filing/0000950170-25-111319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.